Cefcanel daloxate HCl

Cefcanel daloxate, also known as KY-109, is a pro-drug to improve oral absorption of KY-087. The antimicrobial activities of KY-087 against clinically isolated Gram-positive organisms were superior to those of CEX and CCL. The antimicrobial activities of KY-087 against Gram-negative organisms, such as Enterobacter sp., Serratia, and Pseudomonas sp., were less active. KY-087 showed dose-related bactericidal activity against Staphylococcus aureus and Escherichia coli. The therapeutic efficacy of KY-109 against experimental intraperitoneal infections caused by Gram-positive and Gram-negative organisms in mice was comparable to that of CEX but inferior to that of CCL. In experimental granuloma pouch models in rats and kidney infection in rabbits, therapeutic efficacy of KY-109 was either comparable or superior to that of CEX and CCL.

Product information

CAS Number: 92602-21-6

Molecular Weight: 698.19

Formula: C27H28ClN5O9S3

Smiles: Cl.C[C@H](N)C(=O)O[C@H](C1C=CC=CC=1)C(=O)N[C@H]1[C@H]2SCC(CSC3=NN=C(C)S3)=C(C(=O)OCC3OC(=O)OC=3C)N2C1=O

InChiKey: HFVATKYQUGKLGL-PCQLZLFJSA-N

InChi: InChI=1S/C27H27N5O9S3.ClH/c1-12(28)24(35)41-20(15-7-5-4-6-8-15)21(33)29-18-22(34)32-19(25(36)38-9-17-13(2)39-27(37)40-17)16(10-42-23(18)32)11-43-26-31-30-14(3)44-26;/h4-8,12,18,20,23H,9-11,28H2,1-3H3,(H,29,33);1H/t12-,18+,20+,23+;/m0./s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: To be determined

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

References:

1. Cazzola M. Novel oral cephalosporins. Expert Opin Investig Drugs. 2000 Feb;9(2):237-46. doi: 10.1517/13543784.9.2.237. PMID: 11060674.
2. Köhler W, Schenk P. Cephalosporinbehandlung der Sinusitis maxillaris [Cephalosporin treatment of maxillary sinusitis]. Laryngorhinootologie. 1995 Jun;74(6):355-60. German. doi: 10.1055/s-2007-997757. PMID: 7662079.
3. Grunfeld A, Sinclair P, Nicolle L; Canadian Tonsillitis Study Group. Cefcanel daloxate versus penicillin in acute streptococcal pharyngotonsillitis. Can J Infect Dis. 1994 May;5(3):119-24. doi: 10.1155/1994/531572. PMID: 22346486; PMCID: PMC3250823.
4. Edwall B, Slettevold L, Thurmann-Nielsen E, Walstad R, Torrång A, Dahl K. Pharmacokinetics of oral cefcanel daloxate hydrochloride in healthy volunteers and patients with various degrees of impaired renal function. J Antimicrob Chemother. 1994 Feb;33(2):281-8. doi: 10.1093/jac/33.2.281. PMID: 8182009.
5. Nicolle LE, Hoepelman AI, Floor M, Verhoef J, Norgard K. Comparison of three days' therapy with cefcanel or amoxicillin for the treatment of acute uncomplicated urinary tract infection. Scand J Infect Dis. 1993;25(5):631-7. doi: 10.3109/00365549309008553. PMID: 8284649.

Products are for research use only. Not for human use.